Welcome to our dedicated page for Contineum Therapeutics SEC filings (Ticker: CTNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Contineum Therapeutics, Inc. SEC filings document a clinical-stage biopharmaceutical company developing oral small-molecule therapies for neuroscience, inflammation and immunology indications. The filing record covers PIPE-791 and PIPE-307 clinical disclosures, including trial data, protocol updates and Regulation FD materials tied to the company’s development programs.
Contineum’s filings also address quarterly financial results, proxy governance, board and compensation matters, Nasdaq inducement equity plans, Class A common stock registered on Nasdaq, and financing activity through shelf registration statements, underwritten offerings and sales-agreement arrangements. These documents describe the company’s capital structure, governance framework, risk-related clinical disclosures and material-event reporting.
Form 4 Overview: On 06/26/2025, Contineum Therapeutics (CTNM) filed a Form 4 reporting that non-employee director Sarah Boyce received a stock option grant for 14,750 shares of the company’s Class A common stock at an exercise price of $4.01 per share. The option was issued under the company’s 2024 Equity Incentive Plan as part of the regular non-employee director compensation program.
Key Terms: The option vests in full on the earlier of (i) June 26, 2026 (one-year anniversary of the grant) or (ii) the next regular annual meeting of stockholders, provided Ms. Boyce remains a board member. It expires on 06/25/2035.
Post-Transaction Holdings: Following this transaction, Ms. Boyce beneficially owns 14,750 derivative securities (stock options) directly.
Investor Takeaway: The filing reflects routine director compensation and signals alignment of director incentives with shareholder value; financial impact and dilution are immaterial relative to typical public company share counts.
Contineum Therapeutics, Inc. (CTNM) – Form 4 insider filing
On 26 June 2025, non-employee director Evert B. Schimmelpennink received a routine annual stock-option grant under the company’s 2024 Equity Incentive Plan. The award covers 14,750 shares of Class A Common Stock with an exercise price of $4.01 and expires on 25 June 2035. The option vests in full on the earlier of 26 June 2026 or the next regular annual shareholder meeting, contingent upon continuous board service.
The filing reports no open-market purchase or sale of shares; it solely reflects a compensatory grant made pursuant to the Board’s non-employee director compensation program. Following the grant, the director beneficially owns 14,750 derivative securities directly. No other transactions or changes in ownership were disclosed.
Because the transaction is part of a pre-established compensation policy and involves a small percentage of outstanding shares, it is unlikely to have a material impact on the company’s capital structure or near-term valuation.
Contineum Therapeutics, Inc. (CTNM) – Form 4 insider transaction filed 06/26/2025
Director Todd R. Brady reported the grant of a non-qualified stock option covering 14,750 shares of the company’s Class A common stock at an exercise price of $4.01 per share. The option was issued under the company’s 2024 Equity Incentive Plan as part of the regular Non-Employee Director Compensation Program.
Key terms
- Grant date: 26 Jun 2025
- Vesting: 100 % on the earlier of 26 Jun 2026 (one-year anniversary) or the next annual stockholders’ meeting, contingent on continuous board service
- Expiration: 25 Jun 2035 (10-year term)
- Form of ownership: Direct
- No open-market purchases or sales of common shares were reported in Table I
The filing increases Brady’s reported derivative holdings to 14,750 options; no changes were disclosed for non-derivative share ownership. The transaction is routine board compensation and does not affect the company’s share count, cash position, or operating fundamentals. Investors should view it primarily as a standard alignment mechanism between the director and shareholders rather than a catalyst for valuation change.
Contineum Therapeutics, Inc. (CTNM) – Form 4 Insider Filing
On 26 June 2025, non-employee director Troy A. Ignelzi reported the grant of 14,750 stock options under the company’s 2024 Equity Incentive Plan and Non-Employee Director Compensation Program. The options carry an exercise price of $4.01 per share, expire on 25 June 2035, and will vest in full on the earlier of 26 June 2026 (one-year anniversary) or the next annual shareholders’ meeting, subject to continued board service.
The filing shows no disposition of shares; it solely reflects an automatic annual equity grant to a board member. Following the grant, Ignelzi beneficially owns 14,750 derivative securities (options) and no change in direct common-stock ownership was reported.
Because this is a routine director compensation grant rather than an open-market purchase or sale, the event is generally viewed as neutral from a market-moving perspective.
Contineum Therapeutics (CTNM) – Form 4 Insider Filing
On 06/26/2025, non-employee director Lori Lyons-Williams reported the grant of a stock option covering 14,750 shares of Class A common stock. The option, issued under the company’s 2024 Equity Incentive Plan and the Non-Employee Director Compensation Program, carries an exercise price of $4.01 and expires on 06/25/2035. Vesting occurs in full on the earlier of (i) 06/26/2026 (one-year anniversary of grant) or (ii) the next annual meeting of shareholders, contingent on continued board service. Following the grant, the reporting person beneficially owns 14,750 derivative securities; no common shares were purchased or sold. This represents a routine compensation award and does not alter the company’s share count in the near term.
Contineum Therapeutics, Inc. (CTNM) – Form 4 filing dated June 26, 2025
Non-employee director Olivia C. Ware received an automatic annual stock-option award under the company’s 2024 Equity Incentive Plan. The grant covers 14,750 options to purchase Class A common shares at an exercise price of $4.01 per share. The options vest in full on the earlier of (i) June 26, 2026 (one-year anniversary) or (ii) the next regular annual meeting of stockholders, contingent on continued board service, and expire on June 25, 2035. Following the grant, Ware beneficially owns 14,750 derivative securities, reported as direct ownership. No common shares were bought or sold, and no cash changed hands; the transaction is a routine component of the board’s compensation program and results in only de-minimis dilution to existing shareholders.
Form 4 Overview – Contineum Therapeutics, Inc. (CTNM)
Director Diego G. Miralles reported a routine equity award on 26 June 2025. Under the company’s 2024 Equity Incentive Plan and the Non-Employee Director Compensation Program, he received a stock option for 14,750 Class A shares at an exercise price of $4.01 per share. The option vests in full on the earlier of 26 June 2026 or the next annual shareholder meeting and expires on 25 June 2035. Following the grant, Miralles beneficially owns 14,750 derivative securities, all held directly.
No common shares were bought or sold, and no cash changed hands at the time of grant; the filing merely reflects an incentive-alignment award typical for non-employee directors.
Contineum Therapeutics (Nasdaq: CTNM) filed a routine Form 8-K reporting the voting outcomes of its 2025 virtual Annual Meeting held on June 26, 2025.
Shareholders re-elected Class I directors Sarah Boyce, Troy Ignelzi and Olivia Ware, and ratified Ernst & Young LLP as independent auditor for fiscal 2025. No additional proposals or material events were disclosed.